Masuk tirto.id
Jadikan tirto.id sumber pilihan pencarian Google
We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, "Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy", issued 11-Oct-2025 over PR Newswire, as the release contained erroneous information. (Kelunbiotech said a revised release will be issued later. )
Sumber: www.prnasia.com
Disclaimer: This press release was supplied by a third party. Tirto is not involved in its preparation and bears no responsibility for its content.
Reporter: PR Newswire
Penulis: PR Newswire
Editor: PR Newswire
Penulis: PR Newswire
Editor: PR Newswire
